Share
 
Title
Code
Session Type
Venue
Date Time
Co-Chairs:
13:00
FRAB0101LB
Enhanced infection prophylaxis reduces mortality in severely immunosuppressed HIV-infected adults and older children initiating antiretroviral therapy in Kenya, Malawi, Uganda and Zimbabwe: the REALITY trial
James Hakim, University of Zimbabwe Clinical Research Centre, Zimbabwe
Abstract
Slides

13:12
FRAB0102LB
12-week raltegravir-intensified quadruple therapy versus triple first-line ART reduces viral load more rapidly but does not reduce mortality in severely immunosuppressed African HIV-infected adults and older children: the REALITY trial
Cissy Kityo, Joint Clinical Research Centre, Uganda
Abstract
Slides

13:24
FRAB0103LB
Raltegravir (RAL) 1200 mg once daily (QD) is non-inferior to RAL 400 mg twice daily (BID), in combination with tenofovir/emtricitabine, in treatment-naïve HIV-1-infected subjects: week 48 results
Pedro Cahn, Fundacion Huesped, Argentina
Abstract

13:36
FRAB0104LB
Dolutegravir-lamivudine as initial therapy in HIV-infected, ARV naive patients: 48 week results of the PADDLE trial
Pedro Cahn, Fundacion Huesped, Argentina
Abstract

13:48
FRAB0105
Moderated discussion